Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Compass Therapeutics (CMPX) EBITDA Margin (2024)

Compass Therapeutics' EBITDA Margin history spans 1 years, with the latest figure at 1538.47% for Q2 2024.

  • For Q2 2024, EBITDA Margin changed N/A year-over-year to 1538.47%; the TTM value through Mar 2025 reached 6463.88%, changed N/A, while the annual FY2024 figure was 5788.47%, N/A changed from the prior year.
  • EBITDA Margin for Q2 2024 was 1538.47% at Compass Therapeutics.
  • Across five years, EBITDA Margin topped out at 1538.47% in Q2 2024 and bottomed at 1538.47% in Q2 2024.